IL13 and asthma: For example, treatment with a monoclonal human anti-IL-4Rα antibody dupilumab (which inhibits both IL-13 and IL-4 signaling) has shown significant benefits in patients with otherwise uncontrollable asthma or severe dermatitis [53,54].